Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies

被引:252
作者
Gao, Yu [1 ]
Tan, Lin [1 ,2 ]
Yu, Jin-Tai [1 ]
Tan, Lan [1 ]
机构
[1] Qingdao Univ, Qingdao Municipal Hosp, Sch Med, Dept Neurol, Qingdao, Peoples R China
[2] Ocean Univ China, Coll Med & Pharmaceut, Qingdao, Peoples R China
基金
中国国家自然科学基金;
关键词
Tau; aggregation; phosphorylation; NFTs; Alzheimer's disease; therapy; AGGREGATION INHIBITOR THERAPY; DIET-INDUCED OBESITY; PATHOLOGICAL TAU; MOUSE MODEL; PHOSPHORYLATED TAU; AMYLOID-BETA; IN-VITRO; A-BETA; PROMOTES NEURODEGENERATION; CEREBROSPINAL-FLUID;
D O I
10.2174/1567205014666170417111859
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Alzheimer's disease (AD), the most important progressive neurodegenerative disorder, is characterized by cognitive and behavioral disabilities. Nowadays, tau, as a microtubule-associated protein and a principle neuropathological hallmark of AD, provides us a neoteric perspective to explore further aetiopathogenesis and therapeutic strategy. The hyperphosphorylation and abnormal aggregation of tau, combined with its decreased clearance, form neurofibrillary tangles (NFTs) and exert neurotoxicity in AD. Methods: Recent investigations aim to prevent the deposition of NFT and accelerate the clearance of NFT. Intriguingly, immunization strategies targeting tau effectively ameliorates the tau-associated pathology in AD. In addition, modified therapies targeting tau should be regarded as a potential way to treat AD. These progresses open new avenues for AD. Conclusion: Here, we review the recent literature of potential mechanisms of the tau in AD and discuss the modified therapeutic strategies for AD.
引用
收藏
页码:283 / 300
页数:18
相关论文
共 183 条
[1]   MiR-26b, Upregulated in Alzheimer's Disease, Activates Cell Cycle Entry, Tau-Phosphorylation, and Apoptosis in Postmitotic Neurons [J].
Absalon, Sabrina ;
Kochanek, Dawn M. ;
Raghavan, Venkatesan ;
Krichevsky, Anna M. .
JOURNAL OF NEUROSCIENCE, 2013, 33 (37) :14645-14659
[2]   Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies [J].
Adwan, Lina ;
Subaiea, Gehad M. ;
Basha, Riyaz ;
Zawia, Nasser H. .
JOURNAL OF NEUROCHEMISTRY, 2015, 133 (02) :266-272
[3]   A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease [J].
Agadjanyan, Michael G. ;
Petrovsky, Nikolai ;
Ghochikyan, Anahit .
ALZHEIMERS & DEMENTIA, 2015, 11 (10) :1246-1259
[4]   Why do brains need tau (MAPT)? [J].
Amos, Linda A. .
FEBS JOURNAL, 2014, 281 (21) :IV-V
[5]  
[Anonymous], 2004, NATURE, V430, P631
[6]   Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones [J].
Arimura, N ;
Ménager, C ;
Kawano, Y ;
Yoshimura, T ;
Kawabata, S ;
Hattori, A ;
Fukata, Y ;
Amano, M ;
Goshima, Y ;
Inagaki, M ;
Morone, N ;
Usukura, J ;
Kaibuchi, K .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (22) :9973-9984
[7]   Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future [J].
Ariza, Manuela ;
Kolb, Hartmuth C. ;
Moechars, Dieder ;
Rombouts, Frederik ;
Ignacio Andres, Jose .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (11) :4365-4382
[8]   Depletion of microglia and inhibition of exosome synthesis halt tau propagation [J].
Asai, Hirohide ;
Ikezu, Seiko ;
Tsunoda, Satoshi ;
Medalla, Maria ;
Luebke, Jennifer ;
Haydar, Tank ;
Wolozin, Benjamin ;
Butovsky, Oleg ;
Kuegler, Sebastian ;
Ikezu, Tsuneya .
NATURE NEUROSCIENCE, 2015, 18 (11) :1584-1593
[9]   Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements [J].
Asuni, Ayodeji A. ;
Boutajangout, Allal ;
Quartermain, David ;
Sigurdsson, Einar M. .
JOURNAL OF NEUROSCIENCE, 2007, 27 (34) :9115-9129
[10]   AD genetic risk factors and tau spreading [J].
Avila, Jesus ;
Gomez-Ramos, Alberto ;
Bolos, Marta .
FRONTIERS IN AGING NEUROSCIENCE, 2015, 7